electroCore to Participate at H.C. Wainwright Global Investment Conference
electroCore will join the H.C. Wainwright Global Investment Conference, offering a fireside chat and one-on-one investor meetings.
Rhea-AI Summary
electroCore (ECOR) will participate in the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York.
On Tuesday, September 15, 2026, Co-CEO, President and CFO Joshua Lev will take part in a fireside chat and hold one-on-one meetings with investors. Investors seeking a meeting are asked to contact their H.C. Wainwright sales representative or email electroCore Investor Relations at investors@electrocore.com.
Positive
- None.
Negative
- None.
Key Figures
- Conference participation date
- September 15, 2026
- Fireside chat and one-on-one investor meetings
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKAWAY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel.
On Tuesday, September 15, 2026, Joshua Lev, Co-CEO, President and CFO, will participate in a fireside chat and host one-on-one meetings with investors during the conference.
Investors who wish to request a meeting should contact their sales representative at H.C. Wainwright or reach out to electroCore Investor Relations at investors@electrocore.com.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
